Alpha 2.0
Login Register
» Authors » F N Naguib

F N Naguib

Explore the profile of F N Naguib including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 35
Citations 214
Followers 0
Related Specialties
Biochemistry
Pharmacology
Oncology
Top 10 Co-Authors
M H el Kouni
R F Schinazi
O N Al Safarjalani
S Cha
O M Ashour
N M Goudgaon
R P Panzica
M H Iltzsch
S H Chu
S J Soong
Published In
Biochem Pharmacol
Cancer Res
Cancer Chemother Pharmacol
J Biol Chem
Mol Gen Genet
Affiliations
Soon will be listed here.
Recent Articles
1.
Synthesis of carbocyclic orotidine analogs as potential orotidine decarboxylase inhibitors
Song G, Naguib F, el Kouni M, Chu C
Nucleosides Nucleotides Nucleic Acids . 2002 Jan; 20(12):1915-25. PMID: 11794797
An asymmetric synthesis of carbocyclic orotidine 15 and its monophosphate 16 were accomplished via the key intermediate cyclopentanone 4, which was prepared from D-gamma-ribonolactone in steps. None of synthesized the...
2.
Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for uridine rescue regimens in chemotherapy
Al Safarjalani O, Zhou X, Naguib F, Shi J, Schinazi R, el Kouni M
Cancer Chemother Pharmacol . 2002 Jan; 48(5):389-97. PMID: 11761457
Purpose: The purpose of this investigation was to evaluate the effectiveness of oral 5-(phenylthio)acyclouridine (PTAU) in improving the oral bioavailability of uridine. PTAU is a new potent and specific inhibitor...
3.
Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for chemotherapy
Al Safarjalani O, Zhou X, Naguib F, Goudgaon N, Schinazi R, el Kouni M
Cancer Chemother Pharmacol . 2001 Sep; 48(2):145-50. PMID: 11565561
Purpose: The purpose of this investigation was to evaluate the ability of oral PTAU, 5-(phenylthio)acyclouridine, to increase the concentration of endogenous plasma uridine. PTAU is a new potent and specific...
4.
Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2',3',5'-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy
Ashour O, Naguib F, Goudgaon N, Schinazi R, el Kouni M
Cancer Chemother Pharmacol . 2000 Oct; 46(3):235-40. PMID: 11021741
Purpose: The purpose of this investigation was to study the effects of combining oral 5-(phenylselenenyl)acyclouridine (PSAU) with 2',3',5'-tri-O-acetyluridine (TAU) on the levels of plasma uridine in mice. PSAU is a...
5.
5-phenylthioacyclouridine: a potent and specific inhibitor of uridine phosphorylase
el Kouni M, Goudgaon N, Rafeeq M, Al Safarjalani O, Schinazi R, Naguib F
Biochem Pharmacol . 2000 Aug; 60(6):851-6. PMID: 10930540
5-Phenylthioacyclouridine (PTAU or 1-[(2-hydroxyethoxy)methyl]-5-phenylthiouracil) was synthesized as a highly specific and potent inhibitor of uridine phosphorylase (UrdPase, EC 2.4.2.3). PTAU has inhibition constant (K(is)) values of 248 and 353 nM...
6.
Effect of administration of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on the anti-tumor efficacy of 5-fluoro-2'-deoxyuridine against murine colon tumor C26-10
Ashour O, Naguib F, Goudgaon N, Schinazi R, el Kouni M
Biochem Pharmacol . 2000 Aug; 60(5):687-92. PMID: 10927027
The effect of co-administration of 5-(phenylselenenyl)acyclouridine (PSAU), a new uridine phosphorylase (UrdPase, EC 2.4.2.3) inhibitor, on the efficacy of 5-fluoro-2'-deoxyuridine (FdUrd) was tested against murine colon C26-10 tumor xenografts. In...
7.
Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine
Ashour O, Naguib F, Panzica R, Al Safarjalani O, el Kouni M
Biochem Pharmacol . 2000 Jun; 60(3):427-31. PMID: 10856438
Administration of 200 mg/kg of 5-fluorouracil (FUra) to mice bearing human colon carcinoma DLD-1 xenografts resulted in 100% mortality. Oral administration of 2000 mg/kg of 2',3',5'-tri-O-acetyluridine (TAU), a prodrug of...
8.
Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy
Ashour O, Al Safarjalani O, Naguib F, Goudgaon N, Schinazi R, el Kouni M
Cancer Chemother Pharmacol . 2000 May; 45(5):351-61. PMID: 10803917
Purpose: The purpose of this investigation was to evaluate the efficacy of oral 5-(phenylselenenyl)-acyclouridine (PSAU) in increasing endogenous plasma uridine concentration as well as its ability to improve the bioavailability...
9.
The adenosine transporter of Toxoplasma gondii. Identification by insertional mutagenesis, cloning, and recombinant expression
Chiang C, Carter N, SULLIVAN Jr W, Donald R, Roos D, Naguib F, et al.
J Biol Chem . 1999 Nov; 274(49):35255-61. PMID: 10575012
Purine transport into the protozoan parasite Toxoplasma gondii plays an indispensable nutritional function for this pathogen. To facilitate genetic and biochemical characterization of the adenosine transporter of the parasite, T....
10.
Insertional tagging of at least two loci associated with resistance to adenine arabinoside in Toxoplasma gondii, and cloning of the adenosine kinase locus
SULLIVAN Jr W, Chiang C, Wilson C, Naguib F, el Kouni M, Donald R, et al.
Mol Biochem Parasitol . 1999 Oct; 103(1):1-14. PMID: 10514076
A genetic approach has been exploited to investigate adenylate salvage pathways in the protozoan parasite Toxoplasma gondii, a purine auxotroph. Using a new insertional mutagenesis vector designed to facilitate the...